Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 [zotarolimus] eluting driver coronary stent in de novo native coronary artery lesions.

Next Previous
Trial Profile

Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 [zotarolimus] eluting driver coronary stent in de novo native coronary artery lesions.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR-II

Most Recent Events

  • 08 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 12 May 2010 Planned end date changed from 1 May 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov record.
  • 15 Mar 2010 Five-year pooled analysis of ENDEAVOR programme including results from this trial presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC), according to a Medtronic media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top